Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS
Background/aims: Polycystic ovary syndrome (PCOS) is associated with insulin resistance, adrenal hyperactivity and decreased mental health. We aimed to investigate the changes in adrenal activity, metabolic status and mental health in PCOS during treatment with escitalopram or placebo. Methods: For...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2018-03-01
|
Series: | Endocrine Connections |
Subjects: | |
Online Access: | http://www.endocrineconnections.com/content/7/3/490.full |
id |
doaj-7cc329b6d82943c79571d3af65b735d4 |
---|---|
record_format |
Article |
spelling |
doaj-7cc329b6d82943c79571d3af65b735d42020-11-25T00:15:59ZengBioscientificaEndocrine Connections2049-36142049-36142018-03-017311110.1530/EC-18-0077Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOSDorte Glintborg0Magda Lambaa Altinok1Pernille Ravn2Kurt Bjerregaard Stage3Kurt Højlund4Marianne Andersen5Department of Endocrinology and Metabolism, Odense University Hospital, Odense, DenmarkDepartment of Endocrinology and Metabolism, Odense University Hospital, Odense, DenmarkDepartment of Gynecology and Obstetrics, Odense University Hospital, Odense, DenmarkDepartment of Psychiatry, Odense University Hospital, Odense, DenmarkDepartment of Endocrinology and Metabolism, Odense University Hospital, Odense, DenmarkDepartment of Endocrinology and Metabolism, Odense University Hospital, Odense, DenmarkBackground/aims: Polycystic ovary syndrome (PCOS) is associated with insulin resistance, adrenal hyperactivity and decreased mental health. We aimed to investigate the changes in adrenal activity, metabolic status and mental health in PCOS during treatment with escitalopram or placebo. Methods: Forty-two overweight premenopausal women with PCOS and no clinical depression were randomized to 12-week SSRI (20 mg escitalopram/day, n = 21) or placebo (n = 21). Patients underwent clinical examination, fasting blood samples, adrenocorticotroph hormone (ACTH) test, 3-h oral glucose tolerance test (OGTT) and filled in questionnaires regarding mental health and health-related quality of life (HRQoL): WHO Well-Being Index (WHO-5), Major Depression Inventory (MDI), Short Form 36 (SF-36) and PCOS questionnaire. Results: Included women were aged 31 (6) years (mean (s.d.)) and had body mass index (BMI) 35.8 (6.5) kg/m2 and waist 102 (12) cm. Escitalopram was associated with increased waist (median (quartiles) change 1 (0; 3) cm), P = 0.005 vs change during placebo and increased cortisol levels (cortisol 0, cortisol 60, peak cortisol and area under the curve for cortisol during ACTH test), all P < 0.05 vs changes during placebo. Escitalopram had no significant effect on measures of insulin sensitivity, insulin secretion, fasting lipids, mental health or HRQoL. Conclusion: Waist circumference and cortisol levels increased during treatment with escitalopram in women with PCOS and no clinical depression, whereas metabolic risk markers, mental health and HRQol were unchanged.http://www.endocrineconnections.com/content/7/3/490.fullPCOScortisolmental healthquality of lifePCOSQescitalopramSSRI |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dorte Glintborg Magda Lambaa Altinok Pernille Ravn Kurt Bjerregaard Stage Kurt Højlund Marianne Andersen |
spellingShingle |
Dorte Glintborg Magda Lambaa Altinok Pernille Ravn Kurt Bjerregaard Stage Kurt Højlund Marianne Andersen Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS Endocrine Connections PCOS cortisol mental health quality of life PCOSQ escitalopram SSRI |
author_facet |
Dorte Glintborg Magda Lambaa Altinok Pernille Ravn Kurt Bjerregaard Stage Kurt Højlund Marianne Andersen |
author_sort |
Dorte Glintborg |
title |
Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS |
title_short |
Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS |
title_full |
Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS |
title_fullStr |
Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS |
title_full_unstemmed |
Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS |
title_sort |
adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in pcos |
publisher |
Bioscientifica |
series |
Endocrine Connections |
issn |
2049-3614 2049-3614 |
publishDate |
2018-03-01 |
description |
Background/aims: Polycystic ovary syndrome (PCOS) is associated with insulin resistance, adrenal hyperactivity and decreased mental health. We aimed to investigate the changes in adrenal activity, metabolic status and mental health in PCOS during treatment with escitalopram or placebo.
Methods: Forty-two overweight premenopausal women with PCOS and no clinical depression were randomized to 12-week SSRI (20 mg escitalopram/day, n = 21) or placebo (n = 21). Patients underwent clinical examination, fasting blood samples, adrenocorticotroph hormone (ACTH) test, 3-h oral glucose tolerance test (OGTT) and filled in questionnaires regarding mental health and health-related quality of life (HRQoL): WHO Well-Being Index (WHO-5), Major Depression Inventory (MDI), Short Form 36 (SF-36) and PCOS questionnaire.
Results: Included women were aged 31 (6) years (mean (s.d.)) and had body mass index (BMI) 35.8 (6.5) kg/m2 and waist 102 (12) cm. Escitalopram was associated with increased waist (median (quartiles) change 1 (0; 3) cm), P = 0.005 vs change during placebo and increased cortisol levels (cortisol 0, cortisol 60, peak cortisol and area under the curve for cortisol during ACTH test), all P < 0.05 vs changes during placebo. Escitalopram had no significant effect on measures of insulin sensitivity, insulin secretion, fasting lipids, mental health or HRQoL.
Conclusion: Waist circumference and cortisol levels increased during treatment with escitalopram in women with PCOS and no clinical depression, whereas metabolic risk markers, mental health and HRQol were unchanged. |
topic |
PCOS cortisol mental health quality of life PCOSQ escitalopram SSRI |
url |
http://www.endocrineconnections.com/content/7/3/490.full |
work_keys_str_mv |
AT dorteglintborg adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos AT magdalambaaaltinok adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos AT pernilleravn adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos AT kurtbjerregaardstage adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos AT kurthøjlund adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos AT marianneandersen adrenalactivityandmetabolicriskduringrandomizedescitalopramorplacebotreatmentinpcos |
_version_ |
1725385509629329408 |